List of Lyrica Cr drug patents
Lyrica Cr is owned by Upjohn.
Lyrica Cr contains Pregabalin.
Lyrica Cr has a total of 6 drug patents out of which 0 drug patents have expired.
Lyrica Cr was authorised for market use on 11 October, 2017.
Lyrica Cr is available in tablet, extended release;oral dosage forms.
Lyrica Cr can be used as treatment of postherpetic neuralgia; treatment of neuropathic pain associated with diabetic peripheral neuropathy, treatment of neuropathic pain associated with diabetic peripheral neuropathy; treatment of postherpetic neuralgia.
The generics of Lyrica Cr are possible to be released after 02 May, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10022447 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(3 years from now) | |
| US8945620 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(3 years from now) | |
| US9144559 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(3 years from now) | |
|
US9144559
(Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(4 years from now) | |
|
US10022447
(Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(4 years from now) | |
|
US8945620
(Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(4 years from now) | |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 11 October, 2017
Treatment: Treatment of postherpetic neuralgia; Treatment of neuropathic pain associated with diabetic peripheral neuropathy
Dosage: TABLET, EXTENDED RELEASE;ORAL
LYRICA CR family patents
13
United States
1
Portugal
1
Uruguay
1
Guatemala
1
Spain
1
Brazil
1
Costa Rica
1
IB
1
New Zealand
1
Dominican Republic
1
Norway
1
Argentina
1
Morocco
1
Peru
1
China
1
Taiwan, Province of China
1
Korea, Republic of
1
Hong Kong
1
EA
1
Tunisia
1
South Africa
1
Japan
1
Canada
1
Cyprus
1
Slovenia
1
ME
1
Israel
1
Poland
1
Australia
1
RS
1
Ecuador
1
Denmark
1
Netherlands
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic